| Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia P Dharia, MD Swartz, MB Bernhardt, H Chen, MM Gramatges, PJ Lupo, ... Leukemia & lymphoma 63 (12), 2948-2954, 2022 | 9 | 2022 |
| Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273 V Urdaneta, DB Esposito, P Dharia, MS Moraga, K Anteyi, ... Open Forum Infectious Diseases 11 (3), ofae067, 2024 | 5 | 2024 |
| 2391. Evaluation and Adjudication of Case Reports of Myocarditis After mRNA-1273 Vaccination V Urdaneta, P Dharia, O Akangbe, SS Laurent, D Esposito, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2011, 2023 | | 2023 |
| 2375. Contemporary Patterns and Predictors of Influenza and COVID-19 Vaccination Among US Adults During the COVID-19 Pandemic C Bush, KE Mues, S Desai, B Arakaki, P Dharia, P Ghaswalla, Y Park Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1996, 2023 | | 2023 |
| 2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions M Emile-Backer, V Khamamkar, P Dharia, SS Laurent, CK Zhou, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1978, 2023 | | 2023 |
| 2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population K Anteyi, V Urdaneta, P Dharia, M Emile-Backer, V Khamamkar, ... Open Forum Infectious Diseases 10 (Suppl 2), ofad500. 1958, 2023 | | 2023 |
| Incidence of adverse events of special interest in the pre-COVID and active COVID era as historical comparators for post-marketing safety surveillance of SARS-COV-2 vaccines K Mues, C Bush, D Esposito, D Patel, A Gelman, S Syed, P Dharia, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 398-398, 2022 | | 2022 |
| The impact of data truncation on rates of vaccine-associated adverse events utilizing open and closed claims: Lessons from post-marketing safety surveillance of the SARS-COV-2 … C Bush, D Esposito, D Patel, A Gelman, S Syed, P Dharia, K Mues, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 79-79, 2022 | | 2022 |
| Feasibility assessment of claims databases for pregnancy outcomes P Dharia PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 230-231, 2021 | | 2021 |
| Clinical And Demographic Factors Associated With Peg-Asparaginase-Related Toxicities In Patients With Acute Lymphoblastic Leukemia P Dharia | | 2019 |
